Mar 01, 2021 / 08:20PM GMT
Philip M. Nadeau - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
Good afternoon, and welcome once again to Cowen and Company's, hopefully last, Virtual Healthcare Conference. I'm Philip Nadeau, one of Cowen's biotech analysts, and it's my pleasure to moderate a fireside chat with Dynavax Technologies. We have with us Ryan Spencer, CEO; Michael Ostrach, who is in day 1 of his role as CFO emeritus, is also in the background to answer any questions, should they arise. Ryan, thanks for joining us today.
Questions and Answers:
Philip M. Nadeau - Cowen and Company, LLC, Research Division - MD & Senior Research AnalystFirst, just I wanted to start off with kind of a broad question. Could you give a brief state of the company overview? What are Dynavax's biggest strengths today, its biggest challenges? And what do you think needs to happen to it to continue to create shareholder value?
Ryan Spencer - Dynavax Technologies Corporation - CEO & Director
Well, first, Phil, thanks for
Trustpilot
